Recurrent venous thrombosis - an unusual first presentation of autoimmune polyendocrinopathy syndrome type 3B.

S Afr Med J

Department of Internal Medicine, Steve Biko Academic Hospital and Faculty of Health Sciences, University of Pretoria, South Africa.

Published: December 2023

AI Article Synopsis

  • * Testing for common blood clotting disorders came back normal, but she was found to have autoimmune thyroid disease and deficiencies in iron and vitamin B12, possibly due to pernicious anemia.
  • * The case suggests that high levels of homocysteine from vitamin B12 deficiency could be a factor in her recurrent clots, highlighting the need to investigate this in similar atypical situations.

Article Abstract

A 45-year-old female presented with unprovoked recurrent venous thromboembolism (VTE), in unusual sites, and pancytopenia, posing a complex diagnostic challenge. Work-up for inherited thrombophilia, antiphospholipid syndrome (APLS) and paroxysmal nocturnal haemoglobinuria were unremarkable. Investigations revealed autoimmune thyroid disease, and a mixed iron/vitamin B12 deficiency due to pernicious anaemia and resultant atrophic gastritis. Hyperhomocysteinaemia due to vitamin B12 deficiency was identified as a potential contributor to her recurrent VTE. This case highlights the unusual initial presentation of autoimmune polyendocrinopathy syndrome type 3B (APS-3B) with recurrent thromboembolism, and emphasises the importance of considering hyperhomocysteinaemia in unprovoked and atypical VTE cases.

Download full-text PDF

Source
http://dx.doi.org/10.7196/SAMJ.2024.v114i1.1477DOI Listing

Publication Analysis

Top Keywords

recurrent venous
8
presentation autoimmune
8
autoimmune polyendocrinopathy
8
polyendocrinopathy syndrome
8
syndrome type
8
b12 deficiency
8
recurrent
4
venous thrombosis
4
thrombosis unusual
4
unusual presentation
4

Similar Publications

Introduction Hemodialysis (HD) therapy is a crucial treatment for patients with renal failure but can impact the hemodynamics of antithrombin (AT), a protein essential for regulating hemostasis and preventing thrombosis. Reduced AT activity can lead to thrombus formation at unusual sites and increase the risk of recurrent venous thromboembolism. The loss of AT during HD or hemodiafiltration (HDF) through leakage or adsorption onto dialysis membranes has not been fully investigated, and its effects on AT hemodynamics remain unclear.

View Article and Find Full Text PDF

Background: Reduced-dose anticoagulant therapy for extended treatment of cancer-associated venous thromboembolism (VTE) has been used to avoid bleeding. However, it may increase the risk of recurrent VTE.

Objectives: To study the rate of recurrent VTE and bleeding complications in Thai patients with cancer-associated VTE who were treated with full-dos/e or reduced-dose anticoagulants.

View Article and Find Full Text PDF

Objective: To describe the treatment outcomes of patients who underwent Percutaneous Transluminal Angioplasty (PTA) for Central Vein Occlusive Disease (CVOD) in end-stage kidney disease and determine the association between patient profile and treatment outcomes.

Methods: A single-institution, retrospective review of patients aged 18 and above with end-stage kidney disease who underwent PTA for CVOD in the University of the Philippines - Philippine General Hospital (UP-PGH) from January 1, 2013, to December 31, 2022, was performed. These patients' demographic and clinical profiles were evaluated using means, frequencies, and percentages.

View Article and Find Full Text PDF

Paraganglioma, a catecholamine-producing tumor originating in extra-adrenal paraganglion cells, is rare in children. Although diagnosis of paraganglioma is based on the presence of catecholamine symptoms, some patients lack such symptoms. Delayed diagnosis is associated with tumor growth and invasion of surrounding vessels.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!